Setmelanotide treatment was associated with a significant reduction in MetS-Z-BMI scores between baseline and Week 52 for both adult and pediatric patients with BBS, and those who met weight-reduction thresholds exhibited a greater reduction in MetS-Z-BMI scores compared with those who did not. This evidence concerns the gene BBS2 and metabolic syndrome.